Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
PTC Therapeutics, Inc. (PTCT)  
$37.20 0.07 (0.19%) as of 4:30 Fri 5/24


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 90,552,000
Market Cap: 3.37(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $18.07 - $45.015
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 8
Insider 3/6 Months : 8.6
Guru Rank Number :  538
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 7,700 7,700 7,700
Total Buy Value $0 $198,736 $198,736 $198,736
Total People Bought 0 1 1 1
Total Buy Transactions 0 1 1 1
Total Shares Sold 6,156 52,347 65,013 280,515
Total Sell Value $156,968 $1,453,245 $1,963,077 $12,893,521
Total People Sold 3 8 9 15
Total Sell Transactions 5 27 29 89
End Date 2024-02-25 2023-11-24 2023-05-26 2022-05-26

   
Records found: 568
  Page 18 of 23  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Rothera Mark Chief Commercial Officer   •       –      –    2017-02-16 4 OE $10.85 $33,906 D/D 3,125 28,773     -
   Rothera Mark Chief Commercial Officer   •       –      –    2017-01-17 4 OE $10.85 $33,906 D/D 3,125 25,648     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2017-01-05 4 S $11.82 $922 I/I (78) 2,687     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2017-01-03 4 A $0.00 $0 I/I 720 2,765     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2017-01-03 4 A $0.00 $0 D/D 6,000 16,000     -
   Peltz Stuart Walter Chief Executive Officer   •       •      –    2017-01-03 4 A $0.00 $0 D/D 21,600 28,876     -
   Ong Tuyen Chief Medical Officer   •       –      –    2017-01-03 4 A $0.00 $0 D/D 6,000 6,000     -
   Kovacs Shane William Charles Chief Financial Officer   •       –      –    2017-01-03 4 A $0.00 $0 D/D 9,000 27,850     -
   Boulding Mark Elliott Exec. VP and CLO   •       –      –    2017-01-03 4 A $0.00 $0 D/D 9,000 27,034     -
   Rothera Mark Chief Commercial Officer   •       –      –    2017-01-03 4 A $0.00 $0 D/D 9,600 22,523     -
   Rothera Mark Chief Commercial Officer   •       –      –    2016-11-14 4 OE $10.85 $21,060 D/D 1,941 11,216     -
   Rothera Mark Chief Commercial Officer   •       –      –    2016-10-10 4 OE $10.85 $21,158 D/D 1,950 9,275     -
   Almstead Neil Gregory EVP Research Pharma Ops & Tech   •       –      –    2016-09-27 4 OE $10.85 $108,500 D/D 10,000 10,000     -
   Rothera Mark Chief Commercial Officer   •       –      –    2016-09-26 4 OE $10.85 $23,870 D/D 2,200 7,325     -
   Kovacs Shane William Charles Chief Financial Officer   •       –      –    2016-09-26 4 OE $10.85 $108,500 D/D 10,000 18,850     -
   Schmertzler Michael Director   –       •      –    2016-09-23 4 OE $10.85 $651,000 D/D 60,000 86,766     -
   Rothera Mark Chief Commercial Officer   •       –      –    2016-03-03 4 B $6.23 $12,460 D/D 2,000 5,125 2.74     -
   Rothera Mark Chief Commercial Officer   •       –      –    2016-01-15 4 OE $10.85 $33,906 D/D 3,125 3,125     -
   Rothera Mark Chief Commercial Officer   •       –      –    2015-10-20 5 GA $0.00 $0 I/I 9,216 9,216     -
   Rothera Mark Chief Commercial Officer   •       –      –    2015-10-20 5 GD $0.00 $0 D/D 9,216 0     -
   Rothera Mark Chief Commercial Officer   •       –      –    2015-07-21 4 OE $10.85 $99,994 D/D 9,216 9,216     -
   Southwell David P Director   –       •      –    2015-07-06 4 AS $47.50 $1,121,694 D/D (23,604) 0     -
   Southwell David P Director   –       •      –    2015-07-06 4 OE $10.85 $162,750 D/D 15,000 23,604     -
   Jacobson Allan Steven Director   –       •      –    2015-06-18 4 AS $50.13 $250,650 D/D (5,000) 6,848     -
   Peltz Stuart Walter Chief Executive Officer   •       •      –    2015-06-17 4 OE $10.85 $37,975 D/D 3,500 7,276     -
  568 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 18 of 23
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us